Benznidazole levels in blood vary with age in rats

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 3, 2011, Pages 374-377

  Bulffer, Romina Fernanda ^a   Castro, José Alberto ^a   Fane, Silvia Laura ^a  

^a Centro de Investigaciones Toxicologicos   (Argentina)

Author keywords

Benznidazole; Chagas disease; HPLC; Rat blood

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

AGE; ANIMAL; ARTICLE; BLOOD; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; RAT; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; VALIDATION STUDY;

AGE FACTORS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MICROSOMES, LIVER; NITROIMIDAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TRYPANOCIDAL AGENTS;

ANIMALIA; RATTUS;

EID: 79957937211     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000300021     Document Type: Article

References (29)

1. Aguilar E, Arranz CK, Toranzo EGD, Castro JA 1987. Liver microsomal benznidazole and nifurtimox nitroreductase activity in male rats of different age. Arch Int Pharmacodyn Ther 289: 11-17.
2. Boiani M, Piacenza L, Hernandez P, Boiani L, Cerecetto H, Gonzalez M, Denicola A 2010. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina, Biochem Pharm 79: 1736-1745.
3. Cançado JR 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29-37.
4. Castro JA 2000. Contribution of toxicology to the problem of Chagas' disease (American trypanosomiasis). A year 2000 update. Biomed Environ Sci 13: 271-279.
5. Castro JA, de Toranzo EG 1988. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1: 19-33.
6. Castro JA, Montalto de Mecca M, Bartel LC 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 25: 471-479.
7. Castro JA, Montalto de Mecca M, Bartel LC, Rodríguez C 2008. Efectos laterales tóxicos de los fármacos usados para el tratamiento de la enfermedad de Chagas (tripanosomiasis americana). Un problema recurrente en el tratamiento de las enfermedades tropicales. Boletín de la ATA 22: 24-35.
8. Coura JR, Castro SL 2002. A critical review on Chagas disease che-motherapy. Mem Inst Oswaldo Cruz 97: 3-24.
9. de Toranzo EGD, Castro JA, Franke de Cazzulo BM, Cazzulo JJ 1988. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA; proteins and lipids from Trypanosoma cruzi. Experientia 44: 880-881.
10. Docampo R, Moreno SN 1986. Free radical metabolism of antiparasitic agents. Fed Proceed 45: 2471-2476.
11. Gad SC 2001. Statistics for toxicology. In Principles and methods of toxicology, 4th ed., Raven Press, New York, p. 285-364.
12. Gram TE, Gillette JR 1971. Biotransformation of drugs. In Fundamentals of biochemical pharmacology, Pergamon, Oxford, p. 571-609.
13. Ingelman-Sundberg M 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Phramacol Sci 25: 193-200.
14. Jannin J, Villa L 2007. An overview of Chagas disease treatment. Mem Inst Oswaldo Cruz 102 (Suppl. I): 95-97.
15. Masana M, Toranzo EGD, Castro JA 1984. Reductive metabolism and activation of benznidazole. Biochem Pharmacol 33: 1041-1045.
16. OPS/OMS - Organización Panamericana de la Salud/Organización Mundial de la Salud 1998. Tratamiento etiológico de la enfermedad de Chagas. Conclusiones de una consulta técnica. Rev Pat Trop 28: 247-279.
17. Pinto Dias JC 2000. Epidemiología. In Z Brener, Z Andrade, M Barral-Neto (eds.), Trypanosoma cruzi e doença de Chagas, 2nd ed., Guanabara Koogan, Rio de Janeiro, p. 48-74.
18. Pinto Dias JC 2003. XII Reunión Intergubernamental INCOSUR/Chagas, Santiago de Chile, p. 129-134.
19. Pinto Dias JC, Silveira AC, Schofield CJ 2002. The impact of Chagas disease control in Latin America - A Review. Mem Inst Oswaldo Cruz 97: 603-612.
20. Rassi Jr A, Rassi A, Marin-Neto JA 2009. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz 104 (Suppl. I): 152-158.
21. Rodriguez-Morales AJ 2005. Nuevas perspectivas en el manejo terapéutico de la enfermedad de Chagas. Rev Peru Med Exp Salud Publica 22: 123-133.
22. Scheline R 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25: 451-523.
23. Sosa Estani S, Cura E, Velazquez E, Yampotisc, Segura EL 2009.Etiological treatment of young women infected with Trypanosoma cruzi and prevention of congenital transmission. Rev Soc Bras Med Trop 42: 484-487.
24. Sosa-Estani S, Viotti R, Segura EL 2009. Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104 (Suppl. I): 167-180.
25. Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M 1992. Chagas' disease. Clin Microbiol Rev 5: 400-419.
26. Teixeira ARL, Nascimento RJ, Sturm N 2006. Evolution and pathology in Chagas disease - A Review. Mem Inst Oswaldo Cruz 101: 463-491.
27. Toranzo EGD de, Masana M, Castro JA 1983. Nitroreduction of benznidazol and nifurtimox by rat and human feces. Res Commun Chem Pathol Pharmacol 41: 341-344.
28. Urbina JA 2009. Ergosterol biosynthesis and drug development for Chagas disease. Mem Inst Oswaldo Cruz 104 (Suppl. I): 311-318.
29. Wauthier V, Verbeeck RK, Buc Calderon P 2007. The effect of ageing in cytochrome P450 enzymes: consequences for drug biotransformation in the elderly. Curr Med Chem 14: 745-757.